Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:2249:261-280.
doi: 10.1007/978-1-0716-1138-8_15.

Randomized Controlled Trials 5: Biomarkers and Surrogates/Outcomes

Claudio Rigatto  1 , Brendan J Barrett  2
Affiliations

Randomized Controlled Trials 5: Biomarkers and Surrogates/Outcomes

Claudio Rigatto et al. Methods Mol Biol. 2021.

Abstract

Biomarkers are characteristics that are measured as indicators of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarkers may serve a number of important uses, particularly in diagnosis and prognosis of disease, and as surrogates for clinical outcomes of disease (i.e., outcomes that measure how patient survives, functions, or feels). Establishing the validity of a given biomarker for a specific role requires the conduct of carefully designed clinical studies in which the biomarker and the outcome of interest are measured independently. The design and analysis of such studies is discussed. Surrogate outcomes in clinical trials consist of events or biomarkers intended to reflect important clinical outcomes. Surrogate outcomes may offer advantages in providing statistically robust estimates of treatment effects with smaller sample sizes. However, to be useful, surrogate outcomes have to be validated to ensure that the effect of therapy on them truly reflects the effect of therapy on the important clinical outcomes of interest.

Keywords: Clinical trials; Cohort studies; Statistical methods.

PubMed Disclaimer

References

    1. FDA-NIH Biomarker Working Group (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Food and Drug Administration (US), Silver Spring, MD. https://www.ncbi.nlm.nih.gov/books/NBK326791
    1. Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639 - DOI
    1. Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, Gill K, Walker S (2015) Urinary, plasma, and serum biomarkers’ utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis. Am J Kidney Dis 66:993–1005 - DOI
    1. Sackett D, Haynes R, Guyatt G, Tugwell P (1991) The interpretation of diagnostic data. In: Clinical epidemiology: a basic science for clinical medicine, 2nd edn. Little, Brown and Company, Toronto
    1. Kleinbaum DG (1996) Survival analysis: a self-learning text. Springer-Verlag, New York - DOI

LinkOut - more resources